91 related articles for article (PubMed ID: 28254865)
1. Prospective Evaluation of the Clinical Implications of the Tumor Metabolism and Chemotherapy-Related Changes in Advanced Biliary Tract Cancer.
Jo J; Kwon HW; Park S; Oh DY; Cheon GJ; Bang YJ
J Nucl Med; 2017 Aug; 58(8):1255-1261. PubMed ID: 28254865
[TBL] [Abstract][Full Text] [Related]
2. Metabolic Characteristics of Advanced Biliary Tract Cancer Using 18F-Fluorodeoxyglucose Positron Emission Tomography and Their Clinical Implications.
Cho KM; Oh DY; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ
Oncologist; 2015 Aug; 20(8):926-33. PubMed ID: 26099746
[TBL] [Abstract][Full Text] [Related]
3. Prospective Evaluation of Changes in Tumor Size and Tumor Metabolism in Patients with Advanced Gastric Cancer Undergoing Chemotherapy: Association and Clinical Implication.
Park S; Ha S; Kwon HW; Kim WH; Kim TY; Oh DY; Cheon GJ; Bang YJ
J Nucl Med; 2017 Jun; 58(6):899-904. PubMed ID: 28572288
[TBL] [Abstract][Full Text] [Related]
4. Prognostic and predictive value of metabolic tumor volume on (18)F-FDG PET/CT in advanced biliary tract cancer treated with gemcitabine/oxaliplatin with or without erlotinib.
Choi MK; Choi JY; Lee J; Heo JS; Choi SH; Choi DW; Lee KT; Lee JK; Lee KH; Park JO; Park YS; Lim HY
Med Oncol; 2014 Jul; 31(7):23. PubMed ID: 24909509
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of 18F-FDG PET-CT as a prognostic marker in advanced biliary tract cancer.
Braghiroli MI; Mota JM; Duarte PS; Morita TO; Bariani GM; Nebuloni D; Buchpiguel CA; Hoff PM; Riechelmann RP
Nucl Med Commun; 2018 Mar; 39(3):252-259. PubMed ID: 29381586
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of maximum standardized uptake value measured by pretreatment 18F-FDG PET/CT in locally advanced head and neck squamous cell carcinoma.
Cacicedo J; Fernandez I; Del Hoyo O; Navarro A; Gomez-Iturriaga A; Pijoan JI; Martinez-Indart L; Escudero J; Gomez-Suarez J; de Zarate RO; Perez JF; Bilbao P; Rades D
Clin Transl Oncol; 2017 Nov; 19(11):1337-1349. PubMed ID: 28540535
[TBL] [Abstract][Full Text] [Related]
7. Measuring treatment response to systemic therapy and predicting outcome in biliary tract cancer: comparing tumor size, volume, density, and metabolism.
Sahani DV; Hayano K; Galluzzo A; Zhu AX
AJR Am J Roentgenol; 2015 Apr; 204(4):776-81. PubMed ID: 25794066
[TBL] [Abstract][Full Text] [Related]
8. Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy is useful to predict a more accurate prognosis of advanced biliary tract cancer.
Cho KM; Park H; Oh DY; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ
Oncotarget; 2017 Jan; 8(2):2329-2341. PubMed ID: 27911876
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study.
Zhu AX; Meyerhardt JA; Blaszkowsky LS; Kambadakone AR; Muzikansky A; Zheng H; Clark JW; Abrams TA; Chan JA; Enzinger PC; Bhargava P; Kwak EL; Allen JN; Jain SR; Stuart K; Horgan K; Sheehan S; Fuchs CS; Ryan DP; Sahani DV
Lancet Oncol; 2010 Jan; 11(1):48-54. PubMed ID: 19932054
[TBL] [Abstract][Full Text] [Related]
10. Elevated tumor-to-liver uptake ratio (TLR) from
Huang J; Huang L; Zhou J; Duan Y; Zhang Z; Wang X; Huang P; Tan S; Hu P; Wang J; Huang M
Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):1958-1968. PubMed ID: 28812134
[TBL] [Abstract][Full Text] [Related]
11. Predictive Role of Temporal Changes in Intratumoral Metabolic Heterogeneity During Palliative Chemotherapy in Patients with Advanced Pancreatic Cancer: A Prospective Cohort Study.
Yoo SH; Kang SY; Cheon GJ; Oh DY; Bang YJ
J Nucl Med; 2020 Jan; 61(1):33-39. PubMed ID: 31201247
[TBL] [Abstract][Full Text] [Related]
12. Comparison of FOLFIRINOX Chemotherapy with Other Regimens in Patients with Biliary Tract Cancers: a Retrospective Study.
Kus T; Aktas G; Kalender ME; Sevinc A; Camci C
J Gastrointest Cancer; 2017 Jun; 48(2):170-175. PubMed ID: 27714651
[TBL] [Abstract][Full Text] [Related]
13. Patients with recurrent biliary tract cancer have a better prognosis than those with unresectable disease: retrospective analysis of a multi-institutional experience with patients of advanced biliary tract cancer who received palliative chemotherapy.
Ikezawa K; Kanai M; Ajiki T; Tsukamoto T; Toyokawa H; Terajima H; Furuyama H; Nagano H; Ikai I; Kuroda N; Awane M; Ochiai T; Takemura S; Miyamoto A; Kume M; Ogawa M; Takeda Y; Taira K; Ioka T
J Hepatobiliary Pancreat Sci; 2014 Feb; 21(2):98-104. PubMed ID: 23798367
[TBL] [Abstract][Full Text] [Related]
14. Complete Metabolic Response on Interim
Chen S; Ibrahim NK; Yan Y; Wong ST; Wang H; Wong FC
Oncologist; 2017 May; 22(5):526-534. PubMed ID: 28377466
[TBL] [Abstract][Full Text] [Related]
15. The prognostic value of SUV
Diao W; Tian F; Jia Z
Eur J Radiol; 2018 Aug; 105():1-7. PubMed ID: 30017264
[TBL] [Abstract][Full Text] [Related]
16. CA19-9 or CEA Decline after the First Cycle of Treatment Predicts Survival in Advanced Biliary Tract Cancer Patients Treated with S-1 and Cisplatin Chemotherapy.
Lee DW; Im SA; Kim YJ; Yang Y; Rhee J; Na II; Lee KH; Kim TY; Han SW; Choi IS; Oh DY; Kim JH; Kim TY; Bang YJ
Cancer Res Treat; 2017 Jul; 49(3):807-815. PubMed ID: 28111425
[TBL] [Abstract][Full Text] [Related]
17. Second-line chemotherapy in patients with advanced or recurrent biliary tract cancer: a single center, retrospective analysis of 294 cases.
Takahara N; Nakai Y; Isayama H; Sasaki T; Saito K; Oyama H; Kanai S; Suzuki T; Sato T; Hakuta R; Ishigaki K; Takeda T; Saito T; Mizuno S; Kogure H; Tada M; Koike K
Invest New Drugs; 2018 Dec; 36(6):1093-1102. PubMed ID: 30324343
[TBL] [Abstract][Full Text] [Related]
18. Prognostic immunohistochemical biomarkers of chemotherapy efficacy in biliary tract cancer: A systematic review and meta-analysis.
Belkouz A; Labeur TA; Dierks J; Dijk F; van Oijen MGH; Verheij J; van Gulik TM; van de Vijver MJ; Wilmink H; Punt CJA; Klümpen HJ
Crit Rev Oncol Hematol; 2019 Sep; 141():82-94. PubMed ID: 31255992
[TBL] [Abstract][Full Text] [Related]
19. CA19-9 kinetics during systemic chemotherapy in patients with advanced or recurrent biliary tract cancer.
Takahara N; Nakai Y; Isayama H; Sasaki T; Saito K; Noguchi K; Suzuki T; Nakamura T; Sato T; Ishigaki K; Hakuta R; Takeda T; Uchino R; Mizuno S; Kogure H; Tada M; Koike K
Cancer Chemother Pharmacol; 2017 Dec; 80(6):1105-1112. PubMed ID: 29038848
[TBL] [Abstract][Full Text] [Related]
20. The predictive value of
Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
